RT Journal Article
T1 Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis
A1 Gisbert Garzarán, Miguel
A1 Manzano García, Miguel
A1 Vallet Regí, María Dulce Nombre
AB Bone diseases, such as bone cancer, bone infection and osteoporosis, constitute a major issue for modern societies as a consequence of their progressive ageing. Even though these pathologies can be currently treated in the clinic, some of those treatments present drawbacks that may lead to severe complications. For instance, chemotherapy lacks of great tumor tissue selectivity, affecting healthy and diseased tissues. In addition, the inappropriate use of antimicrobials is leading to the appearance of drug-resistance bacteria and persistent biofilms, rendering current antibiotics useless. Furthermore, current antiosteoporotic treatments present many side effects as a consequence of their poor bioavailability and the need to use higher doses. In view of the exposed evidences, the encapsulation and selective delivery to the diseased tissues of the different therapeutic compounds seem highly convenient. In this sense, silica-based mesoporous nanoparticles offer great loading capacity within their pores, the possibility of modifying the surface to target the particles to the malignant areas and great biocompatibility. This manuscript is intended to be a comprehensive review of the available literature on complex bone diseases treated with silica-based mesoporous nanoparticles, whose further development and eventual translation into the clinic could bring significant benefits for our future society.
PB MDPI
SN 1999-4923
YR 2020
FD 2020-01-20
LK https://hdl.handle.net/20.500.14352/6008
UL https://hdl.handle.net/20.500.14352/6008
LA eng
NO RESEARCHER ID S-2443-2016 (Miguel Gisbert Garzarán)ORCID 0000-0001-9815-0354 (Miguel Gisbert Garzarán)RESEARCHER ID K-3719-2014 (Miguel Manzano García)ORCID 0000-0001-6238-6111 (Miguel Manzano García)RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)
NO Unión Europea. H2020
DS Docta Complutense
RD 27 abr 2024